TB Alliance to Launch New Combination Drug Trial

Fauci to Give ‘State of TB’ Address

A group that has pioneered a novel approach to the discovery of critical new drugs for tuberculosis, the Global Alliance for TB Drug Development, or TB Alliance, will hold a briefing that looks at the state of TB research globally and will make an announcement related to the launch of a clinical trial for a new combination of TB drugs.

One in every three people in the world are infected by the bacteria that causes TB, roughly 9 million people each year contract the disease, and an estimated 1.4 million die from it annually.

In addition, the problems around resistance to TB drugs has grown larger in recent years, leading to nearly half-a-million cases of multi-drug resistant TB (MDR-TB), and up to 50,000 cases of extensively drug-resistant TB (XDR-TB).

But momentum has been steadily building in the last decade through research discoveries, creating new hope for better drugs, vaccines and diagnostic tools. Just days before World TB Day and at a time when the US Congress will be discussing the global health budget, senior US policymakers, researchers and TB Alliance leaders will discuss some of the most promising elements in the new research on TB and the importance of US support for that research.

During this event, a high-level panel of experts, including Dr. Anthony S. Fauci, the longtime director of the National Institute of Allergy and Infectious Diseases, will discuss how research could lead to new breakthroughs with the potential of saving millions of lives around the world. This event is sponsored by Critical Path to TB Drug Regimens (CPTR).
WHO:
- Dr. Anthony S. Fauci, Director, National Institute of Allergy and Infectious Diseases
- Dr. Mel Spigelman, President and CEO, Global Alliance for TB Drug Development
- Dr. Janet Woodcock, Director, US Food and Drug Administration’s Center for Drug Evaluation and Research
- Robert Clay, Deputy Assistant Administrator, US Agency for International Development’s Global Health Bureau

WHEN: Monday, March 19, 2012 from 1:30 PM - 3:00 PM
Kaiser Family Foundation, 1330 G. St., NW, Washington, DC
(one block west of Metro Center)

RSVP: For more information or to attend in person, contact Julie-Anne Savarit-Cosenza at Julieanne@burnesscommunications.com or +1 301-280-5720

###

About the Global Alliance for TB Drug Development (TB Alliance)

The Global Alliance for TB Drug Development (TB Alliance) was established in 2000 as a not-for-profit product development partnership to lead the search for new TB cures and catalyze global efforts for new TB drugs that can bring hope, and health, to millions. Its mission is to discover and develop better, faster-acting, and affordable drugs to fight tuberculosis. www.tballiance.org